ResMedMEX:RMD 99 EBITDA Margin % is 39.74% as of Mar. 2026, which is 23% above its 10-year median of 32.42. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,157.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, ResMed ranks better than 95.96% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ResMed's EBITDA for the
three
months ended in Mar. 2026 was MXN10,258 Mil. ResMed's Revenue for the
three
months ended in Mar. 2026 was MXN25,812 Mil. Therefore, ResMed's EBITDA margin for the quarter that ended in Mar. 2026 was 39.74%.
ResMed (MEX:RMD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ResMed EBITDA Margin % Related Terms
ResMed EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ResMed's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, ResMed's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ResMed's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a EBITDA Margin % of 39.74% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ResMed and its competitors. This is 23% above median its historical median of 32.42. Over the past decade, ResMed's EBITDA Margin % has ranged from 27.08 to 39.36. According to the industry distribution chart, ResMed ranks #33 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 4%.
Is ResMed's EBITDA Margin % too high?
ResMed's current EBITDA Margin % of 39.74% is 23% above median its 10-year median of 32.42. Over the past 10 years, this metric has ranged from a low of 27.08 to a high of 39.36. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. ResMed's value of 39.74% is 431.6% above this industry median. Based on the distribution chart, ResMed ranks #33 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's EBITDA Margin % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #33 out of 816 companies for EBITDA Margin %. This places ResMed in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. ResMed's value of 39.74% is 431.6% above this benchmark. Historically, ResMed's own EBITDA Margin % has ranged from 27.08 to 39.36 over the past decade. While the company's 10-year median is 32.42 vs. the industry median of 7.48, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current EBITDA Margin % of 39.74% is 431.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current EBITDA Margin % is 39.74%, which is 23% above median its own 10-year median of 32.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,157.34, compared to a current price of MXN3,716.10 — trading 27.9% below its estimated fair value. The current EBITDA Margin % is 39.74%, which is 23% above median its 10-year median of 32.42 and 431.6% above the Medical Devices & Instruments industry median of 7.48. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current EBITDA Margin % is 39.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 27.9% below its estimated GF Value™ of MXN5,157.34.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
EBITDA Margin %: 39.74% (23% above median its 10-year median of 32.42)
GF Value™: MXN5,157.34 vs. price of MXN3,716.10 (27.9% below fair value)
Industry Position: 431.6% above the Medical Devices & Instruments median (#33 of 816)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
